We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Reference sheet · Viral Peptides · CPC catalog code HIV-012
This sequence carries terminal or reporter modifications (NH2), so no molecular formula or weight is published here — the modified mass must come from the lot certificate of analysis. Residue composition and charge describe the peptide backbone only. Composition figures above are derived arithmetically from the published sequence for the unmodified free peptide. Salt forms (commonly trifluoroacetate or acetate), amidation, and other modifications shift the observed mass — always reconcile against the current lot certificate of analysis.
Volumes for a 1 mg vial of HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF) at common working concentrations. Add solvent slowly down the vial wall and swirl — do not vortex or shake.
Reference standards in the Viral Peptides class are typically shipped as lyophilized powder and stored desiccated at −20 °C protected from light. Once reconstituted in bacteriostatic water or the assay-appropriate buffer, aliquot and store at −80 °C to minimize freeze–thaw cycles. Confirm handling requirements against your institutional biosafety and radiation protocols before use.
HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF) sits within the Viral Peptides research class (CPC reference HIV-012). Viral peptides map to functional regions of viral proteins — fusion peptides, receptor-binding domains, protease cleavage sites, and immunodominant epitopes — enabling targeted studies of entry, replication, and immune recognition. Investigators typically incorporate HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF) as a reference standard, tool ligand, or substrate in the assay contexts listed above. Pseudovirus entry, plaque-reduction, protease-activity, and ELISA readouts.
HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF) (CPC catalog code HIV-012) is a synthetic viral / antiviral research peptide in the viral peptides category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.
Published and internal research programs use HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF) as a reference standard in viral peptides workflows — for example, viral fusion and entry-inhibitor screening and viral protease activity and inhibitor discovery. Human clinical evidence is not established.
No. HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF) is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.
In a viral peptides workflow, HIV-1 env Protein gp41 (1-23) amide (isolates BRU/JRCSF) is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. Pseudovirus entry, plaque-reduction, protease-activity, and ELISA readouts.
Other reference standards in the same class — commonly cross-referenced during assay design and comparator selection.